Qrons Inc. (QRON)
USD 0.15
(-3.23%)
USD 0.15
(-3.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 351.42 Thousand USD | 20.74% |
| 2022 | 291.05 Thousand USD | 60.25% |
| 2021 | 181.62 Thousand USD | 197.72% |
| 2020 | 61 Thousand USD | 331.25% |
| 2019 | 14.14 Thousand USD | 111.9% |
| 2018 | -118.86 Thousand USD | -132.6% |
| 2017 | -51.1 Thousand USD | 66.3% |
| 2016 | -151.65 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 370.16 Thousand USD | 4.06% |
| 2024 Q1 | 355.72 Thousand USD | 1.22% |
| 2023 FY | 351.42 Thousand USD | 20.74% |
| 2023 Q4 | 351.42 Thousand USD | 4.16% |
| 2023 Q2 | 330.88 Thousand USD | 9.93% |
| 2023 Q3 | 337.4 Thousand USD | 1.97% |
| 2023 Q1 | 301 Thousand USD | 3.42% |
| 2022 Q3 | 272.4 Thousand USD | 4.11% |
| 2022 Q4 | 291.05 Thousand USD | 6.84% |
| 2022 FY | 291.05 Thousand USD | 60.25% |
| 2022 Q1 | 240.32 Thousand USD | 32.32% |
| 2022 Q2 | 261.64 Thousand USD | 8.87% |
| 2021 Q3 | 121.73 Thousand USD | 114.53% |
| 2021 Q2 | 56.74 Thousand USD | -42.11% |
| 2021 Q1 | 98.02 Thousand USD | 60.69% |
| 2021 FY | 181.62 Thousand USD | 197.72% |
| 2021 Q4 | 181.62 Thousand USD | 49.2% |
| 2020 Q3 | 17.14 Thousand USD | -81.37% |
| 2020 Q4 | 61 Thousand USD | 255.73% |
| 2020 FY | 61 Thousand USD | 331.25% |
| 2020 Q1 | 68.68 Thousand USD | 385.54% |
| 2020 Q2 | 92.05 Thousand USD | 34.02% |
| 2019 Q1 | -23.76 Thousand USD | 80.01% |
| 2019 FY | 14.14 Thousand USD | 111.9% |
| 2019 Q4 | 14.14 Thousand USD | -48.57% |
| 2019 Q3 | 27.5 Thousand USD | 231.57% |
| 2019 Q2 | 8295.00 USD | 134.91% |
| 2018 Q4 | -118.86 Thousand USD | 31.54% |
| 2018 FY | -118.86 Thousand USD | -132.6% |
| 2018 Q1 | -461.28 Thousand USD | -802.67% |
| 2018 Q2 | -319.43 Thousand USD | 30.75% |
| 2018 Q3 | -173.62 Thousand USD | 45.65% |
| 2017 Q2 | -132.46 Thousand USD | 17.91% |
| 2017 FY | -51.1 Thousand USD | 66.3% |
| 2017 Q3 | -116.28 Thousand USD | 12.21% |
| 2017 Q4 | -51.1 Thousand USD | 56.05% |
| 2017 Q1 | -161.36 Thousand USD | -6.4% |
| 2016 Q4 | -151.65 Thousand USD | 0.0% |
| 2016 FY | -151.65 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 26926.489% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 93.778% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.179% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 240.785% |
| Rebus Holdings, Inc. | 305 Thousand USD | -15.222% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 105.574% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 43.534% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.191% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 1822.006% |
| Skye Bioscience, Inc. | -5.72 Million USD | 106.142% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 97.771% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 91.466% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 12.547% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.97% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 84.327% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 62.097% |
| Mesoblast Limited | 55.85 Million USD | 99.371% |
| Marizyme, Inc. | 18.56 Million USD | 98.107% |
| Genus plc | 190.6 Million USD | 99.816% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 84.282% |
| Pharming Group N.V. | 109.8 Million USD | 99.68% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 59.148% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 71.049% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 48.32% |
| ContraFect Corporation | -6.02 Million USD | 105.832% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -161.014% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 69.585% |
| IMV Inc. | 7.67 Million USD | 95.418% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 93.613% |
| MultiCell Technologies, Inc. | 90.04 USD | -390200.977% |
| ONE Bio Corp. | 9.04 Million USD | 96.113% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 147.88% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 97.285% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 74.31% |
| Q BioMed Inc. | 4.06 Million USD | 91.344% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 98.85% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 65.126% |
| Biomind Labs Inc. | 711.4 Thousand USD | 50.601% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.42% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 82.423% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 97.256% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 2.303% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -151.371% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -1668.898% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 84.04% |
| GB Sciences, Inc. | 1.74 Million USD | 79.888% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 291.213% |
| HST Global, Inc. | 96.79 Thousand USD | -263.071% |
| CSL Limited | 10.52 Billion USD | 99.997% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -70.416% |
| Halberd Corporation | 144.72 Thousand USD | -142.831% |
| Enzolytics Inc. | 981.65 Thousand USD | 64.201% |
| Agentix Corp. | 37.63 Thousand USD | -833.876% |
| Resverlogix Corp. | 6.45 Million USD | 94.552% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 152.211% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.017% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.748% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 95.03% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 87.026% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 103.975% |
| AVAX Technologies, Inc. | -5.9 Million USD | 105.953% |
| Zenith Capital Corp. | 10.06 Thousand USD | -3391.922% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.033% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -75.335% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 85.272% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -113.622% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 2018.479% |
| Kadimastem Ltd | -253.1 Thousand USD | 238.848% |
| Helix BioMedix, Inc. | -2.57 Million USD | 113.674% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 98.267% |
| BioStem Technologies, Inc. | 4.47 Million USD | 92.142% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -74.619% |
| LadRx Corporation | -2.03 Million USD | 117.257% |
| Cell Source, Inc. | 9.23 Million USD | 96.193% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 44.672% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 44.672% |
| NovAccess Global Inc. | 2.17 Million USD | 83.868% |
| Affymax, Inc. | -5.59 Million USD | 106.279% |
| Itoco Inc. | 228.3 Thousand USD | -53.929% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -158.423% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 92.91% |
| Mobile Lads Corp. | 484.23 Thousand USD | 27.426% |
| CytoDyn Inc. | 20.26 Million USD | 98.266% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 54416.383% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 3891.693% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 95.44% |
| SYBLEU INC | 473.71 Thousand USD | 25.815% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 92.115% |
| International Stem Cell Corporation | 2.59 Million USD | 86.431% |
| Bioxytran, Inc. | 1.89 Million USD | 81.493% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -463.067% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 83.886% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 89.766% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 95.891% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 54.514% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 128.114% |
| Neutra Corp. | 52.18 Thousand USD | -573.4% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 114.119% |
| PureTech Health plc | -167.19 Million USD | 100.21% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 243.493% |
| IXICO plc | -4.44 Million USD | 107.907% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 97.342% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.359% |
| CSL Limited | 10.52 Billion USD | 99.997% |
| Cellectis S.A. | -43.81 Million USD | 100.802% |